Celgene Corporation (CELG)

93.67
NASDAQ
Prev Close 93.42
Day Low/High 93.19 / 93.87
52 Wk Low/High 58.59 / 95.44
Exchange NASDAQ
Shares Outstanding 702.45B
Market Cap 65.62B
Div & Yield N.A. (N.A)
Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Searching for Signs of Bottoming Action

Searching for Signs of Bottoming Action

The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.

New Year's Investing Resolutions

New Year's Investing Resolutions

The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.

2 Small Biotech Stocks That Insiders Are Buying

2 Small Biotech Stocks That Insiders Are Buying

Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.

Celgene Is Showing Us a Couple of Interesting Bullish Divergences

Celgene Is Showing Us a Couple of Interesting Bullish Divergences

Celgene could be at a temporary low or it could be starting a new base pattern.

Jim Cramer: I Can't Believe How Badly Many Huge, Important Stocks Have Performed

Jim Cramer: I Can't Believe How Badly Many Huge, Important Stocks Have Performed

I tire of hearing that there has been a correction.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Here's How I'm Playing Biotech Now

Here's How I'm Playing Biotech Now

I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

These Beaten-Down Stocks Could Rebound on Earnings

These Beaten-Down Stocks Could Rebound on Earnings

Upcoming results from these names -- and many others -- should reassure investors.

Celgene Rated New Overweight at Cantor

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Celgene Is Turning Up as Bulls Gain Control

Celgene Is Turning Up as Bulls Gain Control

With biotech names getting some attention this morning a quick review looks like a good idea.

Celgene Price Weakness in Rear-View Mirror

Celgene Price Weakness in Rear-View Mirror

Charts suggest Celgene has put in a low for now.

Jim Cramer: A GLUM Index For Gloomy Markets

Jim Cramer: A GLUM Index For Gloomy Markets

Taking the measure of what's keeping the markets in the dumps.

The Long Decline in Celgene Stock Could Finally Be Over

The Long Decline in Celgene Stock Could Finally Be Over

Here's our new strategy for the shares.

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.

A Rash of Biotech News

The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...

Who Will Win This Game of 'World of Trade Warcraft,' the U.S. or China?

Who Will Win This Game of 'World of Trade Warcraft,' the U.S. or China?

The Chinese have something to lose here, and will not willingly surrender their position of superiority in trade.

Busy Day on Tap: Look for a Solid Jobs Number

It is good once again to be sitting in for Doug Kass on a Friday here on the Daily Diary. Going to be a busy day as we get the monthly jobs report coming out in just over an hour. Although GDP growth (2.3%) did slow in the first quarter from the 3% ...

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.